查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179911

2022-2029 年全球计量雾化吸入器市场

Global Metered Dose Inhaler Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

预计在预测期内（2022 年至 2029 年），计量吸入器的全球市场规模将显着增长。

定量吸入器 (MDI) 是一种加压吸入器，使用推进剂喷雾来输送药物。 它被患有呼吸系统疾病如哮喘、慢性阻塞性肺病（COPD）、慢性支气管炎和肺气肿的人广泛使用。

市场动态

由于哮喘和慢性阻塞性肺病等呼吸系统疾病患者的增加、先进技术的兴起、研发投入的增加以及对药物研发投入的增加等因素，计量吸入器市场正在增长新兴国家的医疗保健基础设施，有望扩大。

呼吸驱动吸入器的采用率不断提高，研发投资不断增加，预计将推动市场增长。

计量吸入器市场的驱动力是技术不断进步、计量吸入器需求增加、研发投资激增、哮喘、慢性阻塞性肺病、慢性支气管炎等慢性呼吸道疾病增多、新兴技术改进新药以及该国医疗基础设施的进步都是因素。 据世界卫生组织称，慢性阻塞性肺病 (COPD) 影响着全世界近 2 亿人。 目前，政府增加用于治疗慢性病的资金正在推动市场的增长。 例如，在欧盟，慢性阻塞性肺病的直接成本约占医疗保健总成本的 6%，占呼吸系统疾病总成本的近 56%。

技术进步正在推动计量吸入器的采用。 呼吸系统疾病的增加，公众对先进呼吸设备的认识提高，例如用于呼吸系统疾病的支气管扩张吸入器比传统治疗具有更多有益特性，以及政府和私营公司增加医疗保健支出。这种增长可能会导致基础设施投资增加，推动计量吸入器市场。

各种新产品的发布和研究正在为市场的增长做出贡献。 例如，2022 年 5 月 17 日，Teva Pharmaceutical Industries Ltd. 旗下公司 Teva Pharmaceuticals 宣布其新制定的短效 BETA-激动剂 (SABA) 临床阈值强调了 SABA 在美国哮喘患者中的实际应用States. 基于研究结果和数字吸入器 ProAir Digihaler（硫酸沙丁胺醇）吸入粉剂的潜力。

与计量吸入器相关的环境或副作用预计会阻碍市场增长。

但是，计量吸入器会释放对环境有害的气体，即氟利昂 (CFC) 和氢氟烷 (HFA) 生物危害性推进剂，对计量吸入器市场的增长产生负面影响。

关于批准这些计量吸入器的严格规则和条例以及与支气管扩张剂相关的震颤、心悸、神经紧张和肌肉痉挛等不良事件阻碍了市场增长。

COVID-19 影响分析

疫情对全球金融预期、运营和危机应对策略产生了负面影响。 COVID-19 的爆发严重影响了医疗保健行业。 由于 COVID 病例的增加，各种研究和临床试验被推迟，计量雾化器市场因 COVID 遭受了巨大损失。 主要製造商已经启动了各种研究和临床试验。 全球正在发生多项举措、产品发布、合作和合併，推动了市场的增长。 例如，2021 年 12 月 17 日，安进公司宣布阿斯利康和安进公司的 Tezspire（tezepelumab-ekko）获得美国食品药品监督管理局（FDA）的批准，用于 12 岁儿童和成人严重哮喘患者的附加维持治疗和更老。宣布它是

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第4章市场动态

  • 市场影响因素
    • 司机
      • 增加呼吸驱动吸入器的渗透率
      • 研发费用增加
      • 不断进步的技术进步
    • 约束因素
      • 与定量吸入药物相关的副作用
    • 商机
    • 影响分析

第5章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 手动加压吸入器
  • 呼吸加压吸入器

第8章药物

  • 肾上腺皮质类固醇
    • 通风孔
    • 维克罗文
    • Azuma 外套
    • 班壳
    • 库巴尔
    • 布地奈德
    • 健美操
  • 支气管扩张剂
    • 长效支气管扩张剂
      • Cerebent（沙美特罗）
      • Foredyl（福莫特罗）
    • 短效支气管扩张剂
      • 文託林
      • 最大空气
      • 普罗文泰
      • Zopenex
      • 专业空气
      • 阿尔彭特
  • 组合药物（皮质类固醇和支气管扩张剂）
    • 信必可
    • 亚代尔

第9章应用

  • 慢性阻塞性肺疾病 (COPD)
  • 支气管哮喘
  • 肺气肿
  • 慢性支气管炎
  • 支气管痉挛
  • 其他

第 10 章（按销售渠道）

  • 医院药房
  • 零售药房
  • 在线药店

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第13章公司简介

  • F. Hoffmann-La Roche
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • AstraZeneca
  • GSK plc
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Boehringer Ingelheim GmbH
  • Cipla Inc.
  • Merck & Co. Inc.
  • Teva Pharmaceutical Industries Ltd.

第14章 计量吸入器的全球市场-DataM

简介目录
Product Code: DMMD52

Market Overview

The global metered dose inhaler market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

A metered-dose inhaler (MDI) is a pressurized inhaler that delivers medication using a propellant spray. It is widely useful for people with respiratory disorders like asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema.

Market Dynamics

The market for metered dose inhalers is driven by the increase in the number of people with respiratory disorders, including asthma and COPD, rising advanced technology, increasing research and development investments and the rising investment in healthcare infrastructure in emerging markets.

The rising adoption of breathing-actuated inhalers and increasing investment in research and development are expected to drive the market's growth.

The metered dose inhaler market is driven by rising advancements in technology, an increase in demand for metered dose inhalers, a surge in research and development investments, an increasing number of chronic respiratory disorders such as asthma, COPD, chronic bronchitis, and improvements in novel drugs using the latest technology along with advances in medical infrastructure in emerging markets. According to the WHO, chronic obstructive pulmonary disease (COPD) affects nearly 200 million people globally. Today, rising funding by government organizations for the treatment of chronic diseases will boost market growth. For instance, in European Union, the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases.

Technological advances have resulted in increasing metered dose inhaler adoption. The rising number of respiratory disorders, and increasing awareness among people about advanced respiratory devices like bronchodilators inhalers and bronchodilators inhalers for respiratory disorders, which have beneficial features over the traditional treatment methods and rising healthcare expenditure by governments and the private sector, could lead to higher infrastructure investments and drive the metered dose inhaler market.

Various novel product launches and research studies contribute to the market's growth. For instance, in May 17, 2022, Teva Pharmaceuticals, a Teva Pharmaceutical Industries Ltd. affiliate, announced its novel study findings based on the usage of short-acting beta agonist (SABA)'s novel established clinical thresholds that highlight real-world use of SABA in asthma patients in the U.S. and the potential for a digital inhaler, ProAir Digihaler (albuterol sulfate) inhalation powder.

The environmental or side effects associated with metered-dose inhalers are expected to hamper the market's growth.

However, metered dose inhalers release environmentally-hazardous gases, namely chlorofluorocarbon (CFC) and hydrofluoroalkanes (HFA) biohazard nature propellants, which negatively impact the metered dose inhalers market's growth.

Stringent rules and regulations for approval of these metered dose inhalers and adverse events such as trembling, palpitations, nervous tension, muscle cramps, and others linked with bronchodilators hinder the market growth.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The metered dose inhaler market has experienced huge losses due to COVID as various research, and clinical trials got postponed due to the increasing cases of COVID. Key manufacturers have started various research and clinical trials. Multiple initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in December 17, 2021, Amgen announced that AstraZeneca and Amgen's Tezspire (tezepelumab-ekko) had been approved by the U.S. Food and Drug Administration (FDA) for pediatric and adult patients aged 12 years and older, add-on maintenance treatment with severe asthma.

Segment Analysis

The bronchodilators segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The bronchodilators segment is the highest market holder in the global metered dose inhaler market. The global metered dose inhaler market is segmented based on medications in corticosteroids, bronchodilators, and combinations (corticosteroids & bronchodilators). The bronchodilator segment is the largest market shareholder due to its rising adoption and demand due to increased respiratory disorders, technological advancements, and novel product launches.

These drugs are the most used inhaled medications. The bronchodilators can be further divided into parasympatholytic (anticholinergic) drugs and sympathomimetic (adrenergic) drugs and are classified as long-acting or short-acting. Anticholinergic drugs block the parasympathetic system, while adrenergic drugs stimulate the sympathetic nervous system. Adrenergic agents cause bronchodilation, and anticholinergic drugs generally block bronchoconstriction. Short-acting bronchodilators are efficacious for 4 to 6 hours, while long-acting drugs generally last about 12 hours.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in July 7, 2020, Novartis announced that its Enerzair Breezhaler (glycopyrronium bromide, indacaterol acetate, and mometasone furoate) first LABA/long-acting muscarinic antagonist fixed-dose combination had been approved by the European Commission (EC) for asthma treatment in adult patients with a combination of a high-dose of an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA), who experienced asthma exacerbations.

Geographical Analysis

North America holds the largest market share in the global metered dose inhaler market.

North America dominates the global metered dose inhaler market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure. According to the Office of Disease Prevention and Health Promotion (ODPHP), around 14.8 million adults in the United States suffered from chronic obstructive pulmonary disease (COPD) in 2020. And 25 million had asthma.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of medications of metered dose inhalers in asthma, and COPD, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the metered dose inhaler market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in September 21, 2020, Teva Respiratory, LLC., Teva Pharmaceutical Industries Ltd. affiliate announced the launch of two digital maintenance inhalers AirDuo Digihaler (salmeterol and fluticasone propionate) and ArmonAir Digihaler (fluticasone propionate) inhalation powder, for patients with asthma. AirDuo Digihaler is a prescription medicine used to prevent wheezing and control asthma symptoms in people 12 years and older.

Competitive Landscape

The metered dose inhaler market is highly competitive with local and global companies' presence. F. Hoffmann-La Roche, AstraZeneca, GSK plc, Pfizer Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim GmbH, Cipla Inc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in April 9, 2020, Cipla Limited announced receiving final approval from the United States Food and Drug Administration (US FDA) for its inhalation aerosol, Albuterol Sulfate 90mcg (base)/actuation's abbreviated new drug application (ANDA). This is Cipla's first AB-rated generic therapeutic similar version of Proventil HFA Inhalation Aerosol of Merck Sharp & Dohme Corp's. It is utilized for treating acute episodes of bronchospasm or asthmatic symptoms prevention.

Novartis AG.

Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Proventil HFA: Proventil HFA (albuterol sulfate) inhalation aerosol is used for reversible obstructive airway disease, like asthma, and to treat or prevent bronchospasm in four years and older patients.

Key Development: In March 14, 2022, Sandoz, a Novartis subsidiary, announced its successful acquisition of Coalesce Product Development Limited, a UK-based drug delivery and medical device development company. With this acquisition, Sandoz acquired Coalesce's significant capabilities that can help build on its existing respiratory medicines portfolio.

The global metered dose inhaler market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising adoption of breathing actuated inhaler
      • 4.1.1.2. Increasing research and development expenditure
      • 4.1.1.3. Rising technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the metered dose inhaler drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Manually-Actuated Pressurized Inhalers *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Breath-Actuated Pressurized Inhalers

8. By Medications

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 8.1.2. Market Attractiveness Index, By Medications
  • 8.2. Corticosteroids*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Flovent
    • 8.2.4. Beclovent
    • 8.2.5. Azmacort
    • 8.2.6. Vanceril
    • 8.2.7. Qvar
    • 8.2.8. Budesonide
    • 8.2.9. Aerobid
  • 8.3. Bronchodilators
    • 8.3.1. Long-Acting Bronchodilators
      • 8.3.1.1. Serevent (salmeterol)
      • 8.3.1.2. Foradil (formoterol)
    • 8.3.2. Short-Acting Bronchodilators
      • 8.3.2.1. Ventolin
      • 8.3.2.2. Maxair
      • 8.3.2.3. Proventil
      • 8.3.2.4. Xopenex
      • 8.3.2.5. ProAir
      • 8.3.2.6. Alupent
  • 8.4. Combination (Corticosteroid & Bronchodilators)
    • 8.4.1. Symbicort
    • 8.4.2. Advair

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Chronic Obstructive Pulmonary Disease (COPD) *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Asthma
  • 9.4. Emphysema
  • 9.5. Chronic Bronchitis
  • 9.6. Bronchospasm
  • 9.7. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. F. Hoffmann-La Roche *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. AstraZeneca
  • 13.3. GSK plc
  • 13.4. Pfizer Inc.
  • 13.5. Amgen Inc.
  • 13.6. Novartis AG
  • 13.7. Boehringer Ingelheim GmbH
  • 13.8. Cipla Inc.
  • 13.9. Merck & Co. Inc.
  • 13.10. Teva Pharmaceutical Industries Ltd.

LIST NOT EXHAUSTIVE

14. Global Metered Dose Inhaler Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us